Outro’s funding included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah Grey Ventures, SemperVirens, Brock Recovery Group and Pave Health Ventures.

Investing in pediatric care is not simply a moral imperative. It is one of the most practical long-term investments the healthcare system can make.

Asking the right questions about community support, caregiving responsibilities, emotional well-being, and the availability of trusted social networks can establish important context for a person’s outcomes — and spark conversations about social needs that might never otherwise take place.

Register for INVEST Digital Health, scheduled for October 29 in Dallas, for an engaging discussion on the impact of consumer-centered care from diagnostics to employer benefits and more.

The FDA recently published draft guidance on pre-market testing for robotically-assisted surgical devices, raising timely discussion around whether hospital infrastructures are capable of supporting increasingly complex systems. 

The pace of change in digital innovation has exposed the ever-widening gap between digital health and Pharma commercial teams. As a result, Pharma is missing out on its ability to significantly improve its commercial model, by focusing on efficiencies vs. truly reinventing.

Earlier detection is valuable, but it creates a duty that does not end when an alert appears in the electronic health record. Health systems need to decide, in advance, how a risk signal becomes a clinically accountable pathway.

Employers are trying to comparison shop in a market where all the price tags are hidden. And most can’t simply switch PBMs to find better pricing for their members.

No longer satisfied with buying pharmacies and clinics, it seems intent on owning the healthcare journey, and perhaps redrawing pharma’s commercialization map.

Perimenopausal anxiety isn't simply in our patients' heads. It's often the result of complex physiologic changes involving hormones, sleep, metabolism, and the nervous system.

I kept hearing “medtech VC is in decline,” so I decided to dig into the data myself. I expected shrinking investor interest, inflated valuations, and a weak exit environment. Instead, I found a more nuanced story.

A new report from ProgenyHealth offers a window into how the business works with commercial and Medicaid plans to close gaps in maternity and NICU care management that traditional programs overlook.

The Trump administration is issuing one-time $90 payments to more than 20 million Medicare beneficiaries to help cover Part B premiums, though the payments may do little to offset rising healthcare costs.

Nobody has ever needed convincing on what to fix. What they've lacked is a way to act on it themselves, in something close to real time instead of on a vendor's roadmap.

Fraud, waste, and abuse (FWA) continue to challenge dental plans as overtreatment, miscoding and inappropriate billing practices drive unnecessary costs and weaken payment integrity. For dental payers, the stakes extend beyond financial losses: these issues can also expose members to unnecessary procedures and consume benefits that should be preserved for appropriate care.

While the immune reset field is mainly focused on depleting pathogenic B cells, ai3Bio is applying its novel approach to inflammatory T cells. The startup’s initial disease targets are autoimmune disorders of the liver that have few treatment options if any at all.

The Trump administration’s ACA fraud crackdown will remove 760,000 people from Marketplace coverage, drawing criticism from healthcare experts and advocates.

Rural patients, Medicaid enrollees, and patients from underrepresented racial and ethnic groups are more likely to go undiagnosed, more likely to be misdiagnosed, and more likely to end up in an emergency department rather than an allergist's office.

In this webinar pharmacy leaders share how hospitals are using stewardship as a sustainability strategy to control costs and ease the load on pharmacists.

Data, behavioral insights, and experimentation can be used to understand how stress, motivation, and trust shape company culture. Positively changing company culture leads to direct improvements in patient health outcomes, clinician wellbeing, and company performance.

Why more than 300,000 missing patient records reveal an engineering problem, not a policy one — and why that's good news.

Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs.

AI could play a meaningful role in advancing social care. Not by replacing people, but by helping them and organizations doing this work move faster, see patterns earlier, and coordinate more effectively. 

Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the conversation

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology.

While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment.

Research from MedCity News and Cotiviti shows robust AI adoption by payers and providers, but what steps are they taking for AI governance and AI weaponized cybersecurity threats?

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year.

As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care? 

As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change.